The anti-TrkC.T1 mAbs may be developed further as antagonists or may be used to eliminate TrkC.T1-expressing cells (which produce TNF-α) at the onset of degenerative diseases such as glaucoma, retinitis pigmentosa, and ALS (Saragovi et al., 2019) (e.g., Müller glial cells in the retina or activated glia in spinal cord). Here, TNF is linked to retinitis pigmentosa.